###begin article-title 0
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Unique spectrum of SPAST variants in Estonian HSP patients: presence of benign missense changes but lack of exonic rearrangements
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 253 259 253 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous disorder that can be an autosomal-dominant, autosomal-recessive, or X-linked disease. The most common autosomal-dominant form of the disease derives from mutations in the SPAST gene.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 272 279 <span type="species:ncbi:9606">patient</span>
The aim of this study was to analyze 49 patients diagnosed with HSP from the Estonian population for sequence variants of the SPAST gene and to describe the associated phenotypes. Healthy control individuals (n = 100) with no family history of HSP were also analyzed. All patient samples were screened using denaturing high performance liquid chromatography (DHPLC) and multiplex ligation-dependent probe amplification (MLPA) assay. Samples with abnormal DHPLC and MLPA profiles were sequenced, with the same regions sequenced in control samples.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
Sequence variants of SPAST were identified in 19/49 HSP patients (38.8%), twelve among them had pathogenic mutations. Within the latter group there was one sporadic case. Eight patients had pure, and four - complex HSP. The twelve variants were identified: seven pathogenic (c.1174-1G>C, c.1185delA, c.1276C>T, c.1352_1356delGAGAA, c.1378C>A, c.1518_1519insTC, c.1841_1842insA) and five non-pathogenic (c.131C>T, c.484G>A, c.685A>G, c.1245+202delG, c.1245+215G>C). Only 2 of these mutations had previously been described (c.131C>T, c.1245+202delG). Three mutations, c.1174-1G>C, c.1276 C>T, c.1378C>A, showed intrafamilial segregation.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
This study identified new variants of the SPAST gene which included benign missense variants and short insertions/deletions. No large rearrangements were found. Based on these data, 7 new pathogenic variants of HSP are associated with clinical phenotypes.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1311 1312 1311 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1427 1428 1427 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1429 1430 1429 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
Hereditary spastic paraplegia (HSP) comprises a group of rare neurodegenerative disorders that are characterized by progressive spasticity and weakness in the legs. The prevalence of HSP in European populations has been reported to vary from 0.5 to 12 individuals per 100,000 [1-4]. For Estonia, a relatively small country with a population of 1.3 million, the prevalence of HSP was recently estimated to be 4.4 per 100,000 [5]. Clinical and genetic heterogeneity, as well as variable severity, are characteristic features of HSP [6], a disorder which is further classified as pure (pHSP) or complex (cHSP). In pHSP, spasticity and motor deficit in the legs, brisk reflexes, and Babinski's sign are often accompanied by deep sensory impairment and sphincter disturbances. In contrast, a number of neurological and extra-neurological features are associated with cHSP which include ataxia, distal amyotrophy, optic neuropathy, cognitive impairment, retinopathy, and gastro-oesophageal reflux [7]. Large inter- and intrafamilial variations in the age of symptom onset, disease progression, and extent of disability have also been observed and are typical of this disorder. Furthermore, HSP can be inherited as an autosomal-dominant (AD-HSP), autosomal-recessive (AR-HSP), or rarely, as an X-linked (X-HSP) trait [8]. The number of different loci associated with HSP includes 18 for AD-HSP, 22 for AR-HSP, and 4 for X-linked HSP [7,9-11].
###end p 10
###begin p 11
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 80 88 80 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spastin </italic>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPG4</italic>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 601 606 601 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPG4 </italic>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPG3A </italic>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
Currently, there are over 150 mutations in the entire SPAST gene (also known as spastin or SPG4) that have been reported to cause at least 40% of all AD-HSP cases [7,12]. In addition, large-scale rearrangements, such as exon deletions, are frequently found to cause HSP, which has been estimated to account for up to 20% of patients with otherwise mutation-negative HSP [13,14]. The spectrum of mutations associated with HSP is compatible with haploinsufficiency being the relevant pathogenic mechanism for this disorder. In addition, there have only been a few benign or unclear missense variants in SPG4 and SPG3A associated with unknown effects [15,16]. Interestingly, missense mutations have been shown to result in phenotypes that are similar to those of exon rearrangements [7].
###end p 11
###begin p 12
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 567 568 567 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 643 649 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 707 715 <span type="species:ncbi:9606">patients</span>
The understanding of genotype-phenotype associations for HSP is expanding rapidly, and although mutations in the SPAST gene were previously thought to produce only AD-pHSP, recent advances in clinicogenetic research have indicated that the clinical presentation of HSP can be extremely variable as both sporadic cases and cHSP forms have been described [17]. Hence, it is important to expand the available knowledge of HSP. Accordingly, a recent epidemiological study of HSP patients in Estonia provided clinical information for a relatively well-defined population [5]. Therefore, the aim of this study was to detect mutations present in the SPAST gene and to characterize the clinical phenotypes of these patients.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Study subjects
###end title 14
###begin p 15
###xml 58 63 <span type="species:ncbi:9606">Human</span>
###xml 188 200 <span type="species:ncbi:9606">participants</span>
This study was approved by the Ethics Review Committee on Human Research of the University of Tartu, Estonia (protocol 110/5, 18.11.2002), and informed consent was obtained from all study participants.
###end p 15
###begin p 16
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 905 906 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 869 881 <span type="species:ncbi:9606">participants</span>
Based on an Estonian epidemiological study that evaluated patients diagnosed with HSP between 2001 and 2005 using a multisource approach [5], and previously described diagnostic criteria for HSP [18,19], 49 patients were included in this study. Twenty-two of the HSP patients belonged to 10 different families, while 10 patients had an unconfirmed family history, and 17 were sporadic cases. All patients were evaluated by at least two experienced neurologists. Neuropsychological evaluations (i.e. Brief Repeatable Battery of Neuropsychological Tests, Beck Depression Inventory, Mini-Mental State Examinations) were performed. Urinary dysfunction was also evaluated and blood samples were collected. Healthy individuals (n = 100) with no family history of HSP those were older than 45 years were used as population controls. All samples were coded. Data for the study participants are presented in Table 1.
###end p 16
###begin p 17
###xml 6 17 <span type="species:ncbi:9606">participant</span>
Study participant data.
###end p 17
###begin title 18
DNA extraction and analysis of sequence variants
###end title 18
###begin p 19
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 696 700 696 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
DNA extraction from whole blood was performed using a High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany). Previously described PCR primers were used for the analysis of the 17 exons and splice sites of the SPAST gene [20]. PCR products of all 49 samples were screened using denaturing high performance liquid chromatography (DHPLC), and SPAST copy number aberrations were detected using multiplex ligation-dependent probe amplification (MLPA) assays (P165, MRC-Holland, The Netherlands) as previously described [13]. Only sporadic cases with normal DHPLC profiles were not sequenced. The same regions in both HSP and control samples were sequenced using the BigDye(R) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). ChromasPro 1.34  was used for sequence analysis.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 96 100 96 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
###xml 20 27 <span type="species:ncbi:9606">patient</span>
Differences between patient clinical parameters were detected using a 2-tailed T-test (Microsoft(R) Office Excel 2003).
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
Genetic analysis of the SPAST gene
###end title 23
###begin p 24
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
According to sequencing results, in 19/49 (38.8%) individuals, 12 nucleotide changes were detected, of which 10 were new (Table 2). All of the individuals were heterozygous for the detected sequence variants without gender predisposition. There were five non-pathogenic and seven presumably pathogenic variants (mutations). One new sequence variant, c.1245+215G>C, and a previously described variant, c.1245+202delG, were detected in both HSP patients and controls. Therefore, both of these intronic variants were considered benign single nucleotide polymorphisms (SNPs). Three pathogenic mutations, c.1174-1G>C, c.1276 C>T and c.1378C>A, showed intrafamilial segregation. All other probable pathogenic mutations (i.e. c.1185delA, c.1352_1356delGAGAA, c.1518_1519insTC, and c.1841_1842insA) were detected in index patients.
###end p 24
###begin p 25
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
Description of SPAST gene variants identified in individuals with HSP.
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
#nomenclature according to HGVS ; *previously described; DHPLC - denaturing high performance liquid chromatography; MLPA - multiplex ligation-dependent probe amplification; S - sequencing; P - pathogenic; NP - non-pathogenic.
###end p 26
###begin title 27
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
Phenotypes of HSP patients with SPAST gene mutations
###end title 27
###begin p 28
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 297 304 <span type="species:ncbi:9606">patient</span>
###xml 376 383 <span type="species:ncbi:9606">patient</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 473 480 <span type="species:ncbi:9606">Patient</span>
###xml 676 683 <span type="species:ncbi:9606">patient</span>
###xml 706 713 <span type="species:ncbi:9606">patient</span>
Pathogenic mutations in the SPAST gene were detected in 12 individuals diagnosed with HSP (Table 3). Nine patients with AD-HSP belonged to four different pedigrees: patients 2109, 2930 and 2931 to pedigree I, patients 2480 and 2482 to pedigree II, patients 2833, 2747 and 2754 to pedigree III and patient 2389 to pedigree IV. There was one clinically confirmed sporadic case (patient 2478). Two subjects with HSP had an unconfirmed family history (patients 2752 and 2753). Patient 2753 was a Russian male with a brother living abroad that exhibited the same walking pattern yet had not been evaluated by neurologists and therefore had not been diagnosed with HSP. Yet another patient was an Armenian male (patient 2752) with an unconfirmed family history of HSP and potentially affected relatives living abroad.
###end p 28
###begin p 29
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
Phenotypes of HSP patients with pathogenic SPAST mutations.
###end p 29
###begin p 30
F - female; M - male; HSP - hereditary spastic paraplegia; pHSP - pure HSP; cHSP - complex HSP; AD - autosomal dominant; NA - not applicable.
###end p 30
###begin p 31
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 140 147 <span type="species:ncbi:9606">patient</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
All patients with pathogenic mutations in the SPAST gene exhibited progressive spastic paraparesis, with 8 patients, including the sporadic patient case, also experiencing bladder disturbances (66%) and 9 having mild or moderate degree of depression (75%). Furthermore, 8 patients with pathogenic SPAST mutations had pHSP and 4 were diagnosed with cHSP and exhibited different degrees of cognitive impairment (33%). There were 3 patients having both - cognitive decline and bladder disturbances (25%) and they were also depressed.
###end p 31
###begin p 32
###xml 433 443 433 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pes cavus </italic>
###xml 68 75 <span type="species:ncbi:9606">patient</span>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 179 186 <span type="species:ncbi:9606">patient</span>
###xml 388 395 <span type="species:ncbi:9606">patient</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
Two females from pedigree III used assistive devices: a 59-year-old patient (2388) used a cane, and a 40-year-old patient (2754) used bilateral crutches. In addition, an Armenian patient (2752) experienced severe neurological effects from cHSP and required a wheelchair, a 70-year-old male (2478) was classified as a sporadic case and used a cane for walking, while a 57-year-old female (patient 2480 from pedigree II) with pHSP had pes cavus and used a unilateral cane. The remaining patients (2109, 2389, 2482, 2747, 2753, 2930, and 2931) walked independently.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST</italic>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 951 959 <span type="species:ncbi:9606">patients</span>
Mutations in the SPAST gene are the most common genetic abnormality associated with HSP. In this study, 12 changes in the SPAST gene were identified, 7 of which represented new pathogenic variants and 2 were previously described. Both missense mutations in the exons (amino acid change) and frameshift mutations (formation of new stop codon) were predominantly identified, which have the potential to alter the protein structure of SPAST. Changes in splice sites are also important and can lead to exon skipping and a reduced stability for aberrantly spliced mRNAs [21,22]. Interestingly, no single deletion or duplication of an exon was detected. Based on previous estimates [13-15] and considering our identification of seven pathogenic "small" mutations, one could have expected to find several exonic rearrangements. The lack of this kind of mutations is hypothesized to be a unique aspect of the Estonian HSP population. A presence in additional patients, however, cannot be excluded.
###end p 34
###begin p 35
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 599 607 <span type="species:ncbi:9606">patients</span>
There were 5 non-pathogenic variants in our study group. Two out of three members (patients 2942 and 2943) of one family without pathogenic SPAST mutations had a substitution c.131C>T. It has previously been suggested that c.131C>T is a benign SNP, yet represents an aggravating disease modifier, since it is usually associated with a pathogenic variant [23,24]. One previously described variant, c.1245+202delG, was identified as a SNP in the HSP patients analyzed as well as in controls [25]. Another sequence variant, c.1245+215G>C, was not previously reported, but since it was detected in both patients and controls, it is also hypothesized to be a SNP. We would also hypothesize that c.484G>A and c.685A>G represent benign missense variants that are rare and specific to the Estonian population.
###end p 35
###begin p 36
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 617 623 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 723 729 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 770 778 770 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo </italic>
###xml 91 94 <span type="species:ncbi:9606">man</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 390 395 <span type="species:ncbi:9606">woman</span>
###xml 397 404 <span type="species:ncbi:9606">patient</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
In our study group, 2 families contained 2 variants in their SPAST gene. For a 33-year-old man with AD-cHSP (patient 2747 from pedigree III), his two affected relatives (his sister and mother - patients 2754 and 2388, respectively) did not have the same sequence variants present in exon 2, yet all affected members of this family had a mutation present in exon 10. Also in one 49-year-old woman (patient 2930 from pedigree I) two variants were found - like two of her relatives with HSP (sister and daughter - patients 2109 and 2931 respectively), she had a splicing mutation at the border of intron 8/exon 9 of the SPAST gene, but additionally a change in exon 5. Hence, these two families contain two mutations in their SPAST gene, one of which is hypothesized to be de novo or a rare SNP. The lack of family segregation of the variants in these pedigrees may be indicative of the non-pathogenic effect of the missense mutations detected in exons 1, 2, and 5 in the Estonian population.
###end p 36
###begin p 37
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 677 683 677 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 937 943 937 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 1140 1146 1140 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 1264 1266 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1445 1447 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1517 1523 1517 1523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 95 102 <span type="species:ncbi:9606">patient</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 663 671 <span type="species:ncbi:9606">patients</span>
###xml 906 914 <span type="species:ncbi:9606">patients</span>
###xml 1016 1024 <span type="species:ncbi:9606">patients</span>
###xml 1126 1134 <span type="species:ncbi:9606">patients</span>
###xml 1310 1318 <span type="species:ncbi:9606">patients</span>
###xml 1503 1511 <span type="species:ncbi:9606">patients</span>
The present study describes phenotypes of HSP patients with SPAST gene mutations. By comparing patient phenotypes, the average age of symptom onset for Estonian patients with SPAST mutations was determined to be 27.8 years (range 3-46), while in other patients with HSP it was 30.0 years (range 5-69) [5]. The mean difference in the age of onset between the two groups was 2.2 years, which was not determined to be significant. Similarly, for previously published data on 356 patients with known mutations in the SPAST gene, no correlation between the age of onset and the type of mutation present could be identified [26]. There was no gender predisposition for patients with SPAST mutations, which included 5 males and 7 females. Previous reports regarding gender have been inconsistent, although studies of large Brazilian pedigrees have found that males were more severely affected by HSP [27,28]. The patients with mutations in the SPAST gene are less likely to have cHSP, and these data further imply that all patients with HSP should be preferentially tested for SPAST mutations. Neurologic co-symptoms associated with patients with SPAST mutations were mainly bladder disturbances, cognitive impairment and depression, being discussed in detail elsewhere [29,30]. Compared with previous reports of HSP patients with bladder dysfunction, only a few other authors described a similar co-existence for HSP with neuropsychological symptoms [19]. The clinical relevance of these observations is that patients with SPAST mutations should receive a more thorough neurological evaluation so that co-symptoms are diagnosed adequately since their symptoms can often be effectively treated.
###end p 37
###begin p 38
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
The limitations of this study should also be considered. For example, samples from all HSP patients identified in the Estonian population studied were unable to be sequenced, which would have increased the confidence of the conclusions of this study. Furthermore, the use of DHPLC to detect changes in the SPAST gene did not reliably identify all of the individuals with abnormal profiles. For example the MLPA assay detected two base pair insertions which were not detected by DHPLC. These differences were confirmed by sequencing. Hence, SPAST variants, especially among sporadic cases, could be missed if DHPLC is the only detection method used. In addition, although healthy controls without any history of HSP in their pedigrees were included in this study, it is still theoretically possible that these controls could develop symptoms of HSP when they are older, although it is extremely unlikely.
###end p 38
###begin title 39
Conclusions
###end title 39
###begin p 40
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPAST </italic>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
In conclusion, the present study describes novel mutations in the SPAST gene of HSP patients, thereby confirming the genetic variability associated with this disorder. A lack of exon deletions/duplications and the presence of rare coding SNPs differentiate this Estonian study group from others previously reported in the literature. Due to the large clinical and genetic variabilities observed [31], and the absence of strict genotype-phenotype correlations, we suggest that in the clinical setting it is insufficient to test individuals with HSP for only known SPAST mutations, and in the case of negative results, additional loci should be sequenced in case other HSP mutations may be present.
###end p 40
###begin title 41
Competing interests
###end title 41
###begin p 42
The authors declare that they have no competing interests.
###end p 42
###begin title 43
Authors' contributions
###end title 43
###begin p 44
Acquired, systemized and controlled the data: MB, RT, SML, KGP, SH. Conceived and designed the investigations: ChB, ER, AM, FC. Performed the investigations and experiments: MB, RT, ER, ESF, CaB. Analyzed the data: MB, RT, ChB, ER, FC, CaB, AM. Wrote the paper: MB, RT. Supervised: AM, SH. The first two authors (MB and RT) contributed equally to the production of this article. All authors read and approved the final manuscript.
###end p 44
###begin title 45
Pre-publication history
###end title 45
###begin p 46
The pre-publication history for this paper can be accessed here:
###end p 46
###begin p 47

###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
###xml 17 25 <span type="species:ncbi:9606">patients</span>
We thank all the patients and control individuals who participated in this study. We are also grateful to Heidi Saulep for her contribution to the experimental work described. This study was supported by the Estonian Science Foundation research grant no. ETF5680; Target Financing SF0180142s08 from the Estonian Ministry of Science and Education; by the European Union through the European Regional Development Fund, in the frame of Centre of Excellence in Genomics, Estonian Biocentre and Tartu University; and FP7 grant ECOGENE no 205419.
###end p 49
###begin article-title 50
Hereditary spastic paraplegia in western Norway
###end article-title 50
###begin article-title 51
The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland
###end article-title 51
###begin article-title 52
Hereditary ataxias and paraplegias in Valle d'Aosta, Italy: a study of prevalence and disability
###end article-title 52
###begin article-title 53
Prevalence of hereditary ataxias and spastic paraplegias in Molise, a region of Italy
###end article-title 53
###begin article-title 54
The prevalence of hereditary spastic paraplegia and the occurrence of SPG4 mutations in Estonia
###end article-title 54
###begin article-title 55
Recent advances in hereditary spastic paraplegia
###end article-title 55
###begin article-title 56
Hereditary spastic paraplegias: an update
###end article-title 56
###begin article-title 57
Hereditary spastic paraparesis: a review of new developments
###end article-title 57
###begin article-title 58
A novel candidate locus on chromosome 11p14.1-p11.2 for autosomal dominant hereditary spastic paraplegia
###end article-title 58
###begin article-title 59
Traffic accidents: molecular genetic insights into the pathogenesis of the hereditary spastic paraplegias
###end article-title 59
###begin article-title 60
Reevaluation of a large family defines a new locus for X-linked recessive pure spastic paraplegia (SPG34) on chromosome Xq25
###end article-title 60
###begin article-title 61
Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia
###end article-title 61
###begin article-title 62
High frequency of partial SPAST deletions in autosomal dominant hereditary spastic paraplegia
###end article-title 62
###begin article-title 63
Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia
###end article-title 63
###begin article-title 64
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Seven novel mutations and four exon deletions in a collection of Norwegian patients with SPG4 hereditary spastic paraplegia
###end article-title 64
###begin article-title 65
Sequence variants in SPAST, SPG3A and HSPD1 in hereditary spastic paraplegia
###end article-title 65
###begin article-title 66
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">and </italic>
Spastin mutations are frequent in sporadic spastic parapares is and their spectrum is different from that observed in familial cases
###end article-title 66
###begin article-title 67
Hereditary Spastic Paraplegia: Advances in Genetic Research
###end article-title 67
###begin article-title 68
Pure hereditary spastic paraplegia
###end article-title 68
###begin article-title 69
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Mutation analysis of the spastin gene (SPG4) in patients with hereditary spastic paraparesis
###end article-title 69
###begin article-title 70
Hereditary spastic paraplegia caused by mutations in the SPG4 gene
###end article-title 70
###begin article-title 71
Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia
###end article-title 71
###begin article-title 72
Clinical features of hereditary spastic paraplegia due to spastin mutation
###end article-title 72
###begin article-title 73
Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations
###end article-title 73
###begin article-title 74
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Mutation analysis of the spastin gene (SPG4) in patients in Germany with autosomal dominant hereditary spastic paraplegia
###end article-title 74
###begin article-title 75
Meta-analysis of age at onset in spastin-associated hereditary spastic paraplegia provides no evidence for a correlation with mutational class
###end article-title 75
###begin article-title 76
Autosomal dominant (AD) pure spastic paraplegia (HSP) linked to locus SPG4 affects almost exclusively males in a large pedigree
###end article-title 76
###begin article-title 77
A multi-exonic SPG4 duplication underlies sex-dependent penetrance of hereditary spastic paraplegia in a large Brazilian pedigree
###end article-title 77
###begin article-title 78
Bladder Dysfunction in Hereditary Spastic Paraplegia: What to Expect?
###end article-title 78
###begin article-title 79
The prevalence of depression in hereditary spastic paraplegia
###end article-title 79
###begin article-title 80
Intrafamilial variability in hereditary spastic paraplegia associated with an SPG4 gene mutation
###end article-title 80

